Effects of Dapagliflozin on Health-Related Quality of Life in Patients with CKD

作者：W Bakker, Hiddo J.L. Heerspink, Niels Jongs, Ricardo Correa-Rotter, Peter Rossing, Robert D. Toto, David C. Wheeler, John J.V. McMurray, Anna Maria Langkilde, Ron T. Gansevoort, Glenn M. Chertow, Priya Vart · 发表于：Journal of the American Society of Nephrology · 年份：2025 · DOI：10.1681/asn.0000000776 · 被引用次数：6 · 研究领域：Diabetes Treatment and Management、Chronic Kidney Disease and Diabetes、Renal Diseases and Glomerulopathies

Key Points In patients with CKD with and without type 2 diabetes, treatment with dapagliflozin slowed the decline in health-related quality of life. The effect was particularly evident on physical health–related quality of life, symptom burden, and the effect of kidney disease. Background Treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin attenuates progression of kidney disease and reduces the risks of heart failure and death in patients with CKD. Data on the effects of dapagliflozin on health-related quality of life (QoL) are limited. Methods Adults with CKD, with and without type 2 diabetes, with eGFR 25–75 ml/min per 1.73 m 2 and urinary albumin-to-creatinine ratio 200–5000 mg/g were randomized to dapagliflozin (10 mg/d) or placebo. We assessed health-related QoL using the Kidney Disease Quality of Life Instrument 36 (KDQOL-36) questionnaire at baseline and at 12, 24, and 36 months. In this prespecified analysis, we determined the overall effects of dapagliflozin versus placebo. Results A total of 4032/4304 (94%) randomized participants (mean age 62 [12] years, 32% female) had information on KDQOL-36 at baseline. Mean scores on the physical health composite (PHC), mental health composite (MHC), and kidney disease symptoms, effects, and burden were similar between randomized groups at baseline. During a median follow-up of 2.3 (interquartile range, 1.9–2.6) years, mean scores were significantly higher in participants randomized to dapaglifloz...